49 research outputs found
Synthesis of different series of small molecules targeting HIV-1 RT, Candida albicans, MAO and G-Quadruplex
My PhD work has been focused towards four different targets: HIV-1 RT, Candida albicans, Monoamine oxidase, and G-Quadruplex. Thus in order to give the reader a clearer exposition this report has been divided in four different chapters. Each of the chapters has his own figures, schemes, tables and references. The main part of my work has been dedicated to HIV-1 RT, thus this chapter is the major and first one
Suppression of lipopolysaccharide-induced COX-2 expression via p38MAPK, JNK, and C/EBPβ phosphorylation inhibition by furomagydarin A, a benzofuran glycoside from Magydaris pastinacea
The phytochemical investigation of the methanol extract of the seeds of Magydaris pastinacea afforded two undescribed benzofuran glycosides, furomagydarins A-B (1, 2), together with three known coumarins. The structures of the new isolates were elucidated after extensive 1D and 2D NMR experiments as well as HR MS. Compound 1 was able to inhibit the COX-2 expression in RAW264.7 macrophages exposed to lipopolysaccharide, a pro-inflammatory stimulus. RT-qPCR and luciferase reporter assays suggested that compound 1 reduces COX-2 expression at the transcriptional level. Further studies highlighted the capability of compound 1 to suppress the LPS-induced p38MAPK, JNK, and C/EBP beta phosphorylation, leading to COX-2 down-regulation in RAW264.7 macrophages
Flavonoids and Acid-Hydrolysis derivatives of Neo-Clerodane diterpenes from Teucrium flavum subsp. glaucum as inhibitors of the HIV-1 reverse transcriptase–associated RNase H function
Bioassay-guided fractionation of the ethyl acetate extract from Teucrium flavum subsp. glaucum, endowed with inhibitory activity towards the HIV-1 reverse transcriptase–associated RNase H function, led to the isolation of salvigenin (1), cirsimaritin (2) and cirsiliol (3) along with the neo-clerodanes teuflavin (4) and teuflavoside (5). Acid hydrolysis of the inactive teuflavoside provided three undescribed neo-clerodanes, flavuglaucins A-C (7-9) and one known neo-clerodane (10). Among all neo-clerodanes, flavuglaucin B showed the highest inhibitory activity towards RNase H function with a IC50 value of 9.1 μM. Molecular modelling and site-directed mutagenesis analysis suggested that flavuglaucin B binds into an allosteric pocket close to RNase H catalytic site. This is the first report of clerodane diterpenoids endowed with anti-reverse transcriptase activity. Neo-clerodanes represent a valid scaffold for the development of a new class of HIV-1 RNase H inhibitors
Synthesis, biological evaluation, and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis: Part 2. Synthesis of rigid pyrazolones
Two series of novel rigid pyrazolone derivatives were synthesized and evaluated as inhibitors of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis. Two of these compounds showed a high activity against MTB (MIC = 4 μg/mL). The newly synthesized pyrazolones were also computationally investigated to analyze if their properties fit the pharmacophoric model for antitubercular compounds previously built by us. The results are in agreement with those reported by us previously for a class of pyrazole analogues and confirm the fundamental role of the p-chlorophenyl moiety at C4 in the antimycobacterial activity
Synthesis, biological evaluation and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis
As a continuation of our previous work that turned toward the identification of antimycobacterial compounds with innovative structures, two series of pyrazole derivatives were synthesized by parallel solution-phase synthesis and were assayed as inhibitors of Mycobacterium tuberculosis (MTB), which is the causative agent of tuberculosis. One of these compounds showed high activity against MTB (MIC = 4 μg/mL). The newly synthesized pyrazoles were also computationally investigated to analyze their fit properties to the pharmacophoric model for antitubercular compounds previously built by us and to refine structure–activity relationship analysis
5-Nitro-3-(2-(4-phenylthiazol-2-yl)hydrazineylidene)indolin-2-one derivatives inhibit HIV-1 replication by a multitarget mechanism of action
In the effort to identify and develop new HIV-1 inhibitors endowed with innovative mechanisms, we focused our attention on the possibility to target more than one viral encoded enzymatic function with a single molecule. In this respect, we have previously identified by virtual screening a new indolinone-based scaffold for dual allosteric inhibitors targeting both reverse transcriptase-associated functions: polymerase and RNase H. Pursuing with the structural optimization of these dual inhibitors, we synthesized a series of 35 new 3-[2-(4-aryl-1,3-thiazol-2-ylidene)hydrazin-1-ylidene]1-indol-2-one and 3-[3-methyl-4-arylthiazol-2-ylidene)hydrazine-1-ylidene)indolin-2-one derivatives, which maintain their dual inhibitory activity in the low micromolar range. Interestingly, compounds 1a, 3a, 10a, and 9b are able to block HIV-1 replication with EC50 < 20 µM. Mechanism of action studies showed that such compounds could block HIV-1 integrase. In particular, compound 10a is the most promising for further multitarget compound development
Exploring new scaffolds for the dual inhibition of HIV-1 RT polymerase and ribonuclease associated functions
Current therapeutic protocols for the treatment of HIV infection consist of the combination
of diverse anti-retroviral drugs in order to reduce the selection of resistant mutants and to allow for
the use of lower doses of each single agent to reduce toxicity. However, avoiding drugs interactions
and patient compliance are issues not fully accomplished so far. Pursuing on our investigation on
potential anti HIV multi-target agents we have designed and synthesized a small library of biphenylhydrazo 4-arylthiazoles derivatives and evaluated to investigate the ability of the new derivatives
to simultaneously inhibit both associated functions of HIV reverse transcriptase. All compounds
were active towards the two functions, although at different concentrations. The substitution pattern
on the biphenyl moiety appears relevant to determine the activity. In particular, compound 2-{3-
[(2-{4-[4-(hydroxynitroso)phenyl]-1,3-thiazol-2-yl} hydrazin-1-ylidene) methyl]-4-methoxyphenyl}
benzamide bromide (EMAC2063) was the most potent towards RNaseH (IC50 = 4.5 mM)- and RDDP
(IC50 = 8.0 mM) HIV RT-associated function
Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey
Introduction: Vascular adhesion protein-1 (VAP-1)/semicarbazide-sensitive amine oxidase (SSAO) is an adhesion protein involved in leukocyte trafficking and inflammatory processes, with a special amine oxidase activity. Inhibitors have been mainly developed for treating chronic inflammatory disorders. The utility of inhibitors as antiangiogenic agents in ophthalmological and oncological diseases is currently under evaluation. SSAO substrates may mimic several insulin effects, although their utility for the treatment of diabetes is still far from being fully understood. Areas covered: This paper reviews the patent literature of SSAO/VAP-1 inhibitors and substrates, for the period of 1990 2010. The current stage of SSAO/VAP-1-interacting agents published in patents is described, along with their chemical structures and pharmacological uses. Expert opinion: SSAO/VAP-1 is a promising anti-inflammatory target. Another important field for therapeutic application of these inhibitors may be ophthalmology, due to their antiangiogenic effects. SSAO substrates might also be of therapeutic value in the treatment of diabetes; however, more extensive research has to be undertaken to validate this approach
2-Acylhydrazino-5-arylpyrrole derivatives: Synthesis and antifungal activity evaluation
The synthesis and antifungal activity of 2-acylhydrazino-5-arylpyrroles 21-62 are described. Pyrrole derivatives 21-62 were evaluated for their antifungal activity towards Candida albicans ATCC 10231 and three Candida non-albicans isolated from clinical specimens. Most of them showed very good antifungall activities against Candidae, having MIC values in the 0.39-3.12 mu g/mL range and enhanced inhibition potency as compared to that of fluconazole. In addition, some of the most active compounds were tested for cytotoxic activities against breast (MCF-7), lung (H-460), and central nervous system (SF-268) human cancer cell lines with the NCI anticancer drug screen. The activity of pyrroles described in this paper, along with the low toxicity, shows promise for the future development of non-toxic new antimycotic agents. The relationship between functional group variation and biological activity of the evaluated compounds is also discussed
Isatin derivatives as new scaffolds for HIV-1 reverse transcriptase associated RNase H and RDDP dual inhibitors
Background. Many AIDS therapeutic agents are targeted to the human immunodeficiency virus (HIV) reverse transcriptase (RT), the multifunctional enzyme which is responsible for the viral genome replication. The HIV-1 RT has two enzymatic associated functions, DNA polymerase and ribonuclease H (RNase H), both essential for genome reverse transcription and, therefore, both attractive targets for drug development. Currently, none of the approved antiviral agents is active on both functions. Hence, the identification of new scaffolds capable to achieve the inhibition of both enzymatic functions is an innovative approach which may reduce the selection of mutant viruses, resistant to single target drugs, and is an attractive challenge for medicinal chemists and virologists.
Methods. We designed and synthesized a series of differently substituted isatin derivatives and tested them on the HIV-1 RT-associated RNase H and DNA polymerase functions and viral replication.
Results. The isatin derivatives inhibited both HIV-1 RT-associated functions in the low micromolar range and they were assessed also on the Y181C and K103N mutant RTs. Mechanism of action studies showed that they do not chelate the divalent ion cofactor and do not interact with the HIV-1 RNase H active site.
Conclusions. The newly synthesized isatin derivatives are a promising scaffold for HIV-1 RT dual inhibitors. They probably bind to an allosteric site without interacting with the HIV-1 RNase H active site. The obtained SAR study will provide significant hints for the determination of the pharmacophoric requirements for the interaction with the viral target and will give new information for hit optimization